Rozel Injection Rozel contains Denosumab, a human monoclonal antibody designed to target and bind to RANKL (receptor activator of nuclear factor kappa-B ligand). By neutralizing RANKL, it prevents osteoclast formation, function, and survival, resulting in reduced bone resorption and increased bone density. It is indicated for treating postmenopausal osteoporosis, bone loss associated with hormone ablation therapy in prostate or breast cancer, and glucocorticoid-induced osteoporosis in patients at high risk for fracture.